Relay Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Relay Therapeutics has a total shareholder equity of $681.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $772.6M and $90.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$688.42m |
| Equity | US$681.74m |
| Total liabilities | US$90.81m |
| Total assets | US$772.55m |
Recent financial health updates
Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation
Aug 03
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Recent updates
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Sep 11Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation
Aug 03Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Financial Position Analysis
Short Term Liabilities: RLAY's short term assets ($704.3M) exceed its short term liabilities ($45.0M).
Long Term Liabilities: RLAY's short term assets ($704.3M) exceed its long term liabilities ($45.8M).
Debt to Equity History and Analysis
Debt Level: RLAY is debt free.
Reducing Debt: RLAY has no debt compared to 5 years ago when its debt to equity ratio was 3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RLAY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RLAY has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 35.1% each year.